drugset / Trial / NCT00668122

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

NCT00668122

Phase 3 Completed 212 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).

Timeline

Start
2004-03
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 500 mg Oral
Subject Ciprofloxacin Small molecule 1000 mg Oral